Ändrat rapportdatum för Q3-rapporten 2007

Rapportdatum för Orexos delårsrapport januari-september 2007 har ändrats. Rapporten kommer att publiceras den 23 oktober 2007.

För ytterligare information, vänligen kontakta:

Zsolt Lavotha, VD och koncernchef
Tel: 018-780 88 12, e-post: zsolt.lavotha@orexo.se

Claes Wenthzel, Vice VD och CFO
Tel: 018-780 88 44, e-post: claes.wenthzel@orexo.se

Om oss

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via selected partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2017 amounted to SEK 643.7 million and the number of employees at year-end was 90. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.


Dokument & länkar